Building healthier futures powered by thoughtful science
We are a highly focused, research-driven biopharmaceutical company working in rare diseases. We're exploring the potential of cutting-edge science as a subsidiary of Nippon Shinyaku Co., Ltd. In Japan.
Advancing rare disease research
Inspired by our own families, as well as the individuals we aim to provide with treatment, NS Pharma is conducting advanced research in rare diseases, including exon-skipping technology, to offer new, effective treatment options for Duchenne. We’re also developing JAK1 inhibition for the potential treatment of eosinophilic granulomatosis with polyangiitis (EGPA).
Therapeutic areas
NS Pharma is working to have an important impact on the lives of patients with rare diseases. Our therapeutic areas encompass neurological diseases and inflammatory diseases.
Scientific approaches
Harnessing the power of innovative science can help bring new treatments to patients with rare diseases. NS Pharma is developing therapies through exon-skipping, cell therapy and JAK1 inhibition technology.
Therapeutic areas
NS Pharma is working to have an important impact on the lives of patients with rare diseases. Our therapeutic areas encompass neurological diseases and inflammatory diseases.
Scientific approaches
Harnessing the power of innovative science can help bring new treatments to patients with rare diseases. NS Pharma is developing therapies through exon-skipping, cell therapy and JAK1 inhibition technology.
From our blog
Press Release / July 1, 2025
NS Pharma Announces Strategic Alliance with Boston Children’s Hospital to Develop New Therapies for Rare Diseases
Press Release / May 14, 2025
FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment
Press Release / April 18, 2025
FDA Grants Orphan Drug Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis
Press Release / July 1, 2025
NS Pharma Announces Strategic Alliance with Boston Children’s Hospital to Develop New Therapies for Rare Diseases
Press Release / May 14, 2025
FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment
Press Release / April 18, 2025
FDA Grants Orphan Drug Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis
A warm welcome to Jon Yochum, our new National Account Director!
Jon joins us most recently from Sanofi, bringing with him over 20 years of experience in strategic account management across multiple therapeutic areas.
We believe collaboration drives progress, so we are very proud to announce a new strategic alliance with @BostonChildrens Hospital to advance innovative therapies for rare diseases!
Meet Demet Pilge, our new Associate Director of HCP Marketing!
Demet brings 20+ years of marketing experience across Psychiatry, Neurology, Oncology, ENT & Respiratory. In her free time, she enjoys traveling with her family and unwinding with piano.
We're excited to be in Minneapolis for the #HopeInFocus Conference!
This inspiring event brings together families, researchers & professionals from around the world to share insights & explore advances in #InheritedRetinalDiseases.